Accera Enters Development Agreement with Nestle Purina PetCare
Accera's preclinical studies on AC-1203, the veterinary version of AC-1202, have shown that it has unique, potent therapeutic effects on certain neurological conditions, like CCD, as well as certain behavior and metabolism associated with aging.
09/01/07 Accera Inc. announced an agreement under which it has granted Nestle Purina PetCare Global Resources, Inc. the right to develop its proprietary compound, AC-1203, for application to healthy aging and wellness in dogs and other companion animals.
It is a well-documented fact that dogs suffer a condition known as Canine Cognitive Dysfunction (CCD), which resembles Alzheimer's disease in humans. Accera's preclinical studies on AC-1203, the veterinary version of AC-1202, have shown that it has unique, potent therapeutic effects on certain neurological conditions, like CCD, as well as certain behavior and metabolism associated with aging.
Under the terms of the agreement, Purina will be responsible for future development, manufacturing, and commercialization costs for both the dog and the companion animal market. Purina will make an upfront payment and additional milestone payments to Accera based on defined development and commercialization achievements. Financial terms of the agreement were not disclosed.
Dr. Steve Orndorff, president and CEO of Accera, said, "As the world leader in pet food and pet care products Purina is well-positioned to take AC- 1203 into commercial development for the worldwide pet care market. This partnership builds on Accera's research experience with AC-1203 which shows that it has the potential to improve the lives of aging dogs."
